Method of producing an autoprobiotic formulation and use thereof

The method for producing autoprobiotic formulations from indigenous microbiota addresses the safety and efficacy concerns of industrial probiotics by genetically analyzing and selecting safe indigenous bacteria strains, resulting in personalized products that effectively enhance gut health and treat disorders.

WO2024231722A1PCT designated stage expired Publication Date: 2024-11-14NIKOLAEV FEDOR
View PDF 20 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2023/059333
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2023-09-21
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Existing probiotics based on industrial strains face biological incompatibility and safety concerns due to foreign antigens, leading to transient gut residence and potential adverse effects, necessitating the development of personalized autoprobiotics from indigenous microbiota with species identification and pathogenic determinant analysis for high safety and efficacy.

Method used

A method for producing autoprobiotic formulations involving fecal microbiota sampling, selective culture growth, genetic analysis for pathogenic determinant exclusion, and selection of genetically safe indigenous bacteria strains, which are then prepared as monocomponent or polycomponent products for specific health conditions.

Benefits of technology

The method ensures high safety and efficacy of autoprobiotic products by utilizing genetically safe, indigenous bacteria strains that are specifically selected for each individual, enhancing gut microbiome health and treating various disorders with reduced risk of adverse effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000039_0001
    Figure IMGF000039_0001
  • Figure IMGF000020_0001
    Figure IMGF000020_0001
  • Figure IMGF000025_0001
    Figure IMGF000025_0001
Patent Text Reader

Abstract

The present invention relates to the field of microbiology and personalized medicine and discloses a method for producing a novel personalized autoprobiotic formulation based on indigenous microbiota of a subject, characterized with high safety and efficacy, and personalized according to health state of the subject. The invention further relates to methods for improving the health of the subject using microorganisms indigenous to the subject's gut microbiome.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] METHOD OF PRODUCING AN AUTOPROBIOTIC FORMULATION AND USE THEREOF

[0002] FIELD OF THE INVENTION

[0003] The present invention relates to the field of microbiology and personalized medicine and provides methods for producing an autoprobiotic formulation based on indigenous microbiota of a subject and methods for improving the health of a subject using microorganisms indigenous to the subject’s gut microbiome.

[0004] BACKGROUND OF THE INVENTION

[0005] In recent years, vast experience has been accumulated regarding the use of probiotics for treatment or prevention of a wide range of disorders. Some studies report successful use of probiotic therapy in gastroenterology, pulmonology, rheumatology, cardiology [1-4], The majority of works consider the probiotics comprising industrial strains of microorganisms [5-7], However, it should be noted that the use of the probiotics based on industrial strains is associated with a number of risks. Artificially grown species comprise foreign antigens and are rejected due to biological incompatibility. Generally, biotechnological probiotics fail to penetrate into intestinal epithelium and therefore remain in the gut lumen transiently as food microbiota [7], This fact is acknowledged by probiotic manufacturers stating that their supplements mainly stimulate growth of the obligate microorganisms [8],

[0006] It is currently hypothesized that oral probiotics can potentially cause four types of adverse effects, namely, development of infections associated with strains comprised in a certain probiotic formulation, metabolic disorders, excessive immunostimulation of inflammation in the gastrointestinal tract, formation of new clones of bacterial strains due to pathogenicity factors gene transfer.

[0007] The disadvantages of the existing probiotics dictate the need for development of new drugs and therapies based on indigenous strains of microorganisms and characterized with high safety and efficacy. One of the approaches is engineering of autoprobiotics (personalized probiotics) lacking the disadvantages of conventional probiotics, produced on the basis of indigenous microbiota of an individual and characterized by high affinity to intestinal epithelium of the said individual. A distinctive feature of autoprobiotics is also their affinity for a patient: it is expected that the probiotic strain, obtained individually from the patient, will gently and effectively contribute to the restoration of the normal (initial) state of the gastrointestinal tract.

[0008] The possibility to use indigenous microbiota strains for prevention of dysbiosis following antibiotic treatment was reported in 1987 by V.M. Korshunov et al. in the patent publication SU 1286212 [9], It was shown that indigenous strains of Lactobacillus and Bifidobacterium isolated from patients before the antibiotic therapy and given immediately after the therapy are highly effective for prevention of dysbiosis and reduction of treatment duration of enteric infections. However, the said approach does not imply species identification for strains selected as autoprobiotics, and consequently, it is impossible to control the quality of the final product.

[0009] The patent publication RU 2139070

[0010] discloses an autoprobiotic complex based on the diluted intestinal content of patients and enriched with lacto- and bifidobacterium species and the method for its preparation. However, the said invention has two main disadvantages: the unknown final composition of the autoprobiotic complex, which comprises a set of different bacterial strains, and, consequently, impossibility of assessing safety of the produced autoprobiotic complex for the patient.

[0010] The patent publication RU 2460778

[0011] describes a method for producing an autoprobiotic based on Enterococcus faecium comprising: taking a fecal microbiota sample from the subject, growing the culture on a selective nutrient medium, identifying and selecting colonies typical for Enterococcus faecium, obtaining a pure culture of Enterococcus faecium, identifying species and analyzing the presence of pathogenic determinants by PCR, selecting nonpathogenic clones of Enterococcus faecium which are genetically safe and physiologically functional, optionally, depositing of the selected clones in a cryobank at a temperature < 75 °C for not more than 1 year. The use of such autoprobiotic for prevention of post-infectious irritable bowel syndrome described in the patent publication RU 2553372

[0012] ; its application for reducing the severity of non-motor symptoms in patients suffering from Parkinson's disease reported in RU 2734718

[0013] , Similarly, the patent publication RU 2546253

[0014] discloses a method for obtaining a personalized autoprobiotic product based on indigenous strains of Lactobacilli and a method for treating irritable bowel syndrome comprising administering to a subject the said autoprobiotic product. However, the claimed autoprobiotics are monocomponent formulations and the said inventions do not imply the possibility of producing poly component autoprobiotics based on any species of indigenous microorganisms found in the subject’s microbiota. According to another approach, RU 2505304

[0015] and RU 2580002

[0016] describe methods for producing autoprobiotics based on indigenous live strains of lacto- and bifidobacterium species isolated from the host intestine. Further, RU 2661624

[0017] and RU 2727444

[0018] consider methods for isolating the total human intestinal microbiota applied for fecal transplantation and its use, e.g., for treatment of irritable bowel syndrome. However, since the said approaches do not imply species identification for strains selected as autoprobiotics or for total fecal microbiota transplants the final composition of the product is unknown and its safety cannot be evaluated.

[0011] Preferably, development of personalized probiotics on the basis of indigenous microbiota of an individual shall comprise species identification (e.g., by genetic methods) and analysis of pathogenic determinants in order to obtain safe product with high efficacy suitable for treatment of the said individual. Species identification methods, inter alia using genetic approaches described, for example, in the patent publications RU 2508406, RU 2680268, US 10381112, US 10395777, US 10920283, WO 2009123736, WO 2020087046 [19-25], However, the said inventions do not imply analysis of pathogenic determinants for species included in probiotic products thus making it impossible assessing the safety of the final compositions.

[0012] The patent publication US 2021381024

[0026] (also published as WO 2020086413) provides improved methods for enhancing the health of a subject through restoration of the subject’s gut microbiome. In particular, it discloses a personalized method comprising re-inoculating the subject’s gastrointestinal (GI) tract with beneficial microorganisms isolated from the subject’s own unique GI microbiome. Advantageously, the method provides for personalized treatments for a variety of health conditions that are associated with the health and balance of the intestinal microbiome. In a certain embodiment, the claimed method comprises taking a sample from the subject’s GI tract, wherein the sample comprises a microbial community; analyzing the sample to determine the identity of microbial species present within the microbial community, and to determine the ratio of each species with respect to the other species of the microbial community; determining which microbial species within the community are undesirable, including overgrown commensal bacteria, certain yeasts and fungi, and which microbial species are beneficial, and isolating the beneficial species; cultivating the beneficial species to produce a microbial culture with increased cell concentration; and reintroducing the microbial culture with increased cell concentration into the subject’s GI tract. However, the determination which microbial species within the community are undesirable does not comprise analyzing the presence of any pathogenic determinants, e,g, by PCR, and is accomplished mainly by standard microbiological methods.

[0013] Therefore, there is a need to develop new safe autoprobiotic products with high efficacy and therapies for improving the health of a subject using microorganisms indigenous to the subject’s gut microbiome addressing one or more disadvantages of the prior art. It is expected that future success in this field depends on the ability to design specific products or therapy protocols personalized for an individual instead of developing general nonspecific approaches.

[0014] SUMMARY OF THE INVENTION

[0015] It is the objective of the present invention to provide a novel personalized probiotic product based on indigenous microbiota of a subject and characterized with high safety and efficacy, a method for producing thereof and improved methods for enhancing the health of a subject using microorganisms indigenous to the subject’s gut microbiome.

[0016] In one embodiment, the invention provides a method of producing an autoprobiotic formulation based on indigenous microbiota of a subject, comprising the steps of taking a fecal microbiota sample from the subject, growing the sample on selective culture medium, identifying the strains of indigenous bacteria, obtaining pure cultures of identified strains, which are further analyzed by genetic methods for assessing their safety, followed by exclusion of pathogenic determinants and selection of genetically safe strains of indigenous bacteria, which are further prepared as an autoprobiotic product. In some embodiments, the said method optionally comprises a stage of storage of genetically safe bacterial strains in a cryobank before preparing the final composition.

[0017] In one embodiment, the specific strains of indigenous bacteria to be included into the autoprobiotic formulation are selected by a medical specialist after receiving assessment data for a current health condition of the subject. In some embodiments, said assessment data comprises test results.

[0018] In another embodiment, the autoprobiotic formulation is monocomponent or polycomponent. In some embodiments, the autoprobiotic formulation comprises or consists of one or more strains belonging to species Lactobacillus spp., Lactococcus spp., Enterococcus spp., Streptococcus spp., Bifidobacterium spp., E.coli, Akkermansia spp., Hafnia alvei.

[0019] In yet another embodiment, the invention relates to an autoprobiotic formulation based on indigenous microbiota of a subject comprising genetically safe strains of indigenous bacteria. According to further embodiment the autoprobiotic formulation is produced by the claimed method. In yet another embodiment the formulation is intended for oral, topical or intravaginal administration.

[0020] In another embodiment, the invention provides an autoprobiotic formulation for use in the method of treating a disease or disorder in a subject in need thereof. In one embodiment, the specific strains of indigenous bacteria to be included into the autoprobiotic formulation for treating a disease or disorder in said subject are selected by a medical specialist after receiving assessment data for a current health condition of the subject. In some embodiments, said assessment data comprises test results. In certain embodiments, the autoprobiotic formulation for use in the method of treating a disease or disorder in a subject is administered orally, on the skin or into vaginal cavity.

[0021] These and other embodiments are described in details below.

[0022] BRIEF DESCRIPTION OF THE DRAWINGS

[0023] The accompanying drawings illustrate the embodiments of the presently disclosed invention and together with the description disclose the principles of the invention.

[0024] FIG. 1 demonstrates the content of marker bacteria in patients with IBS and healthy people.

[0025] FIG. 2 shows representation of different phyla in the gut of IBS patients and healthy people.

[0026] FIG. 3 shows percentage ratio of different phyla in the gut of IBS patients and healthy people.

[0027] FIG. 4 shows representation of genera Faecalibacterium (A), Bacteroides (B) and Desulfovibrio (C) in the gut of IBS patients and healthy people.

[0028] FIG. 5 demonstrates growth of enterococci on chromogenic and azide media. As a result, three isolated clones of enterococci corresponding by their cultural characteristics to E. faecium were obtained.

[0029] FIG. 6 demonstrates the number of defecations per week before and after probiotic and autoprobiotic therapy. FIG. 7 demonstrates changes in PD NMS scale before and after probiotic and autoprobiotic therapy.

[0030] FIG. 8 shows changes in gut microbiota in PD patients after autoprobiotic therapy (bacteriological study). Y-axis - 1g CFU / g, p < 0.05.

[0031] FIG. 9 shows the content of marker bacteria before and after probiotic and autoprobiotic therapy (bacteriological study), p < 0.05

[0032] FIG. 10 demonstrates the content of marker bacteria before and after probiotic and autoprobiotic therapy, p < 0.05.

[0033] FIG. 11 demonstrates the results of the total comparison of bacterial genes in respect of phylogenetic affinity (mean values).

[0034] FIG. 12 demonstrates the results of the total comparison of bacterial genes in respect of phylogenetic affinity (individuals, healthy volunteers and PD patients, before and after autoprobiotic therapy).

[0035] FIG. 13 shows comparison of groups by alpha-biodiversity analysis (diversity within a community at the species level).

[0036] FIG. 14 demonstrates the activity of digestive enzymes before and after autoprobiotic therapy.

[0037] DETAILED DESCRIPTION OF THE INVENTION

[0038] Generally, the present invention describes a method for producing a novel autoprobiotic formulation based on indigenous microbiota of a subject, characterized with high safety and efficacy, and personalized according to health state of the subject, and methods for improving the health of a subject and treating a certain disease or disorder using microorganisms indigenous to the subject’s gut microbiome. I. DEFINITIONS

[0039] Throughout the present specification and claims the terms “comprise” and “have” and variations thereof such as “comprises”, “comprising”, “has” and “having” are to be interpreted inclusively. The terms “a”, “an” and “the” used in the context of describing the invention cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by the context.

[0040] Each interval disclosed in this application is understood as a set of all numbers belonging to this interval. Therefore, each interval includes all and each value belonging to this interval, as well as any of its subintervals. If not indicated otherwise, the boundary points of an interval are assumed to be part of the interval.

[0041] In general, the term “probiotic” refers to live microbial cells or preparations, containing live microbial cells with a beneficial effect on the health of a subject.

[0042] As used herein, the terms “autoprobiotic formulation” or “autoprobiotic” mean a composition or product made from beneficial human bacteria based on the own (indigenous) microbiota of a subject. In the preferred embodiment, the autoprobiotic formulation is characterized by 100 % compatibility with the organism of the subject thus eliminating the risk of allergies and / or seriously reducing other possible adverse effects.

[0043] The term “personalized probiotic” herein refers to a product, in the preferred aspect an autoprobiotic, developed individually for a subject based on assessment data for a current health condition of the subject and aimed at solving a specific problem.

[0044] The terms “microbiota”, “microflora” and “microbiome” are used interchangeably herein and refer to a community of microorganisms that inhabit a particular environment, preferably, the human’s body. In some embodiments, the term “microbiome” describes the collective genomes of microorganisms making up microbiota of an organism.

[0045] As used herein, the terms “indigenous microbiota”, “indigenous bacteria”, “indigenous strain” and “indigenous microorganism” mean specific microorganisms produced, growing, living or occurring naturally in a certain environment, preferably, in the human’s body.

[0046] The term “pathogenic determinants” herein refers to any factors produced or expressed by microorganisms capable of causing a disease or disorder in a subject. Consequently, the term “genetically safe strain” describes particular microorganisms, which do not produce or express any pathogenic determinants.

[0047] As used herein, the terms “monocomponent” and “polycomponent” refer to autoprobiotic formulations consisting of one or more species of microorganisms in the formulation, respectively.

[0048] The term “assessment data” herein describes any information relating to a current health state of a subject received by a medical specialist by any appropriate method. In the preferred embodiment, said assessment data comprises test results.

[0049] As used herein, the terms “administering” or “administration” mean the introduction of an autoprobiotic formulation according to the invention to a subject in need thereof. In the preferred embodiment, these terms refer to oral, topical or intravaginal ways of administration.

[0050] The terms “subject”, “patient” and “individual” are used interchangeably herein and refer to an animal, such as a mammal, more preferably a human.

[0051] As used herein, the terms “treat” and “treatment” refer to inhibiting or reducing the development of a pathological condition, disorder or disease in a subject or its clinical symptoms by means of a certain therapy.

[0052] Other features and advantages of the invention will be obvious from the following description of the preferred embodiments and from the claims. All references cited herein are hereby incorporated by reference.

[0053] II. DESCRIPTION OF PREFERRED EMBODIMENTS

[0054] The present invention provides a method of producing an autoprobiotic formulation based on indigenous microbiota of a subject, comprising the following steps: (a) taking a microbiota sample from the subject, wherein said sample comprises indigenous bacteria of said subject; (b) growing a microbiota sample from stage (a) on selective culture medium; (c) identifying the strains of indigenous bacteria obtained at stage (b); (d) obtaining pure cultures of identified strains from stage (c); (e) genetically analyzing the strains of indigenous bacteria obtained at stage (d) for assessing their safety; (f) excluding the presence of pathogenic determinants; (g) selecting genetically safe strains of indigenous bacteria obtained at stage (d); (h) preparing an autoprobiotic formulation based on genetically safe strains of indigenous bacteria obtained at stages (e)-(g).

[0055] In accordance with an embodiment of the present invention, a microbiota sample can be collected by any standard method known to a specialist skilled in the art. Preferably, the said sample is a stool sample of the subject for gut microbiota samples. However, it can also be collected via endoscopy for gut microbiota samples or swab samples for other locations.

[0056] Further, the sample is cultivated on selective culture medium to produce microbial cultures having an increased cell concentration for subsequent species identification. The cultivation is accomplished using standard microbiological medium known to a specialist skilled in the art, e.g. solid agar medium or liquid culture medium. In certain embodiments, the medium can optionally include growth factors, biostimulants, vitamins, essential amino acids, inorganic elements, antibiotics, markers or other additives. In some embodiments, the cultivation is carried out at any suitable optimal temperature. In certain embodiments, the cultivation is carried out at about 15 to 60 °C, at about 20 to 50 °C, or at about 25 to 40 °C. Preferably, the cultivation is carried out at about 32 to 37 °C. In another embodiment, the cultivation continues for about 12- 168 hours, for about 24-120 hours, for about 36-144 hours, or for about 48-96 hours. Preferably, the cultivation continues for about 24-48 hours.

[0057] In accordance with an embodiment of the present invention, species identification of produced microbial cultures is carried out using standard microbiological approaches known to a specialist skilled in the art. In certain embodiments, species identification is accomplished by genetic and / or molecular biology methods, including PCR.

[0058] In one embodiment, the stage of obtaining pure cultures of previously identified indigenous strains is aimed to increase cell concentration of target microorganisms and implies the use of standard microbiological medium, such as solid agar medium or liquid culture medium, optionally, enriched with additives (growth factors, biostimulants, vitamins, essential amino acids, inorganic elements, antibiotics, markers, etc.). In some embodiments, the cultivation is carried out at any suitable optimal temperature. In certain embodiments, the cultivation is carried out at about 15 to 60 °C, at about 20 to 50 °C, or at about 25 to 40 °C. Preferably, the cultivation is carried out at about 32 to 37 °C. In another embodiment, the cultivation continues for about 12-240 hours, for about 24-168 hours, for about 36-216 hours, for about 48-192 hours, or for about 72-120 hours. Preferably, the cultivation continues for about 48-96 hours.

[0059] Further, the strains of indigenous bacteria obtained as pure cultures undergo genetic analysis for assessing their safety. In certain embodiments, the genetic analysis is aimed at excluding the presence of antibiotic resistance genes and pathogenic determinants in target microorganisms, i.e. factors produced or expressed by them capable of causing a disease or disorder in a subject. In some embodiments, said technique implies the use of standard molecular genetic methods comprising, inter alia, PCR with primers homologous to known pathogenic determinants, antibiotic resistance genes and sequencing of specific parts of indigenous bacteria genome. In the preferred embodiment, the pathogenic determinants are genes encoding one or more factors selected from hemolysins, adhesins, proteases, cytolysins, toxins and antibiotic resistance genes. The applied approach allows selecting genetically safe strains of indigenous bacteria lacking any pathogenic determinants and antibiotic resistance genes, which are further used for preparing the end product.

[0060] In certain embodiments, the method of producing an autoprobiotic formulation according to the present invention further comprises a stage of storage of genetically safe bacterial strains in a cryobank before preparing the final composition. In some embodiments, the deposition of strains in the cryobank is carried out at any suitable storage temperature. In some embodiments, the deposition is carried out at about -18 to -200 °C, at about -25 to -180 °C, at about -40 to -150 °C, at about -60 to -120 °C, at about -80 to -160 °C, or at about -90 to -190 °C. In the preferred embodiment, the deposition is carried out at about -20 to -195 °C. In the most preferred embodiment, the deposition is carried out at -80 °C. In another embodiment, the storage period continues from 1 to 5 days, from 3 to 15 days, from 10 to 20 days, or from 15 to 30 days. In yet another embodiment, the storage period continues from 1 to 3 months, from 2 to 6 months, from 4 to 8 months, from 3 to 10 months, or from 2 to 12 months. In yet another embodiment, the storage period continues from 1 to 2 years, from 1 to 5 years, from 2 to 6 years, from 2 to 8 years, or from 1 to 10 years. In the preferred embodiments, the storage period is from 1 day to 1 year, more than 1 year, or unlimited. In some embodiments, genetically safe strains of indigenous bacteria are stored in the cryobank as pure cultures. On demand of a patient or if such a need arises deposited strains can be retrieved and further formulated as the autoprobiotic product based on indigenous microbiota of the said patient. In accordance with an embodiment of the present invention, the autoprobiotic formulation is monocomponent or polycomponent, i.e. consists of one or more species of microorganisms, respectively. The end product can comprise any appropriate beneficial indigenous species of a subject’s microbiota aimed at solving a specific problem. In the preferred embodiment, the autoprobiotic formulation without any limitations comprises or consists of one or more of species Lactobacillus spp., Lactococcus spp., Enterococcus spp., Streptococcus spp., Bifidobacterium spp., E.coli, Akkermansia spp., Hafnia alvei.

[0061] In one embodiment, the autoprobiotic formulation according to the present invention is personalized. It means that specific strains of indigenous bacteria to be included into the autoprobiotic formulation are selected by a medical specialist after receiving assessment data for a current health condition of the subject taking into account a particular health problem to be solved. In one embodiment, said assessment data for the current health condition of the subject comprises test results. In some embodiments, the test results can include, but not limited to, one or more obtained from bacteriological culturing of the subject’s microbiota sample, assessment of current microbiota composition by quantitative PCR, metagenomic microbiota analysis or combined gas chromatography mass-spectrometry analysis. Optionally, other applicable tests comprise blood tests, endoscopy, biopsy, genetic tests, CT scanning or MRI. It is expected, that final composition made from beneficial bacteria based on the indigenous microbiota of the subject in view of the subject’s health state is characterized by high level (up to 100 %) of compatibility, safety, efficacy, decreased risk of allergies and reduced probability of side effects.

[0062] In yet another embodiment, the invention provides an autoprobiotic formulation based on indigenous microbiota of a subject comprising genetically safe strains of indigenous bacteria. According to further embodiment the autoprobiotic formulation is produced by the claimed method. The said autoprobiotic formulation may further comprise an excipient, diluent or carrier. Suitable excipients, diluents or carriers without any limitations relate to a pharmaceutically acceptable material or carrier such as the liquid or solid excipient, diluent or solvent, and may comprise sugars (lactose, glucose, sucrose, etc.), starch (corn starch or potato starch), cellulose and its derivatives, malt, gelatin, glycols (e.g. propylene glycol), polyols (glycerol, sorbitol, mannitol, etc.), buffering agents, isotonic saline, ethyl alcohol and other non-toxic biocompatible substances. In some embodiments, the autoprobiotic formulation may optionally comprise one or more prebiotics, i.e. substances promoting the growth of beneficial bacteria in the gastrointestinal tract, such as carbohydrates (e.g., inulin). In one embodiment, the autoprobiotic formulation according to the present invention is provided in the form of a capsule, tablet, solution, cream, powder or suppository. In accordance with an embodiment of the present invention, the autoprobiotic formulation may be administered to a patient in any effective, convenient manner including oral, rectal, intravaginal, topical administration routes. In some embodiments, the autoprobiotic formulation may be administered by oral gavage. In the preferred embodiment, the autoprobiotic formulation is administered through oral, topical or intravaginal administration routes to specific parts of the patient’s body in need thereof. A medical specialist should individually determine the dosage, regimen and duration of treatment for each clinical case depending on the characteristics of the patient to be treated.

[0063] In yet another embodiment, the invention provides an autoprobiotic formulation for use in the method of treating a disease or disorder in a subject in need thereof, optionally comprising receiving assessment data for a current health condition of the subject by a medical specialist before administering the autoprobiotic formulation. In one embodiment, the specific strains of indigenous bacteria to be included into the autoprobiotic formulation for treating a disease or disorder in said subject are selected by the medical specialist after receiving assessment data for the current health condition of the subject. In some embodiments, said assessment data comprises test results. In certain embodiments, the test results include without any limitations one or more obtained from bacteriological culturing of the subject’s microbiota sample, assessment of current microbiota composition by quantitative PCR, metagenomic microbiota analysis or combined gas chromatography mass-spectrometry analysis. Other acceptable tests can further comprise blood tests, endoscopy, biopsy, genetic tests, CT scanning or MRI.

[0064] In certain embodiments, the autoprobiotic formulation for use in the method of treating a disease or disorder may be administered to a patient in a number of routes, including oral, rectal, intravaginal or topical. In some embodiments, the autoprobiotic formulation may be administered by oral gavage. In the preferred embodiment, the autoprobiotic formulation is administered orally, on the skin or into vaginal cavity.

[0065] The dosage, regimen and duration of treatment should be individually determined by a specialist for each clinical case taking into account a patient’s health state and specific symptoms. In certain embodiments, the autoprobiotic formulation for use in the method of treating a disease or disorder is administered to the patient once a day, twice a day, three times a day, four times a day, five times a day, every two days, every three days, every four days, every five days, once a week, two times a week, three times a week, four times a week, five times a week, every two weeks, every three weeks, or every four weeks. In the preferred embodiment, the autoprobiotic formulation is administered to the patient once a day, twice a day or three times a day. In certain embodiments, the autoprobiotic formulation for use in the method of treating a disease or disorder is administered to the patient for one week, for two weeks, for three weeks, for a month, for two months, for three months, for four months, for five months, for six months, for seven months, for eight months, for nine months, for ten months, for eleven months, or for a year. In the preferred embodiment, the autoprobiotic formulation is administered to the patient for one week, for two weeks, for three weeks or for a month. In certain embodiments, the autoprobiotic formulation for use in the method of treating a disease or disorder is administered to the patient continuously or in administration cycles.

[0066] In certain embodiments, the autoprobiotic formulation is used for treating a disease or disorder in a subject in need thereof, including without any limitations dysbiosis, inflammatory bowel disease, irritable bowel syndrome, obesity, impaired glucose tolerance, diabetes mellitus, viral infection, bacterial infection, cancer, condition after antibiotic treatment, condition after chemotherapy, condition after radiation therapy, neurodegenerative disorder, gynecological disorders, acne, atopic dermatitis (eczema), psoriasis, gastritis, cholelithiasis dental diseases and other pathological conditions accompanied by a disturbance of intestinal microbiota.

[0067] The present disclosure is illustrated by the following non-limiting examples.

[0068] EXAMPLES

[0069] EXAMPLE 1. MULTIPLE AUTOPROBIOTIC STRAINS ISOLATION

[0070] A stool sample of a healthy patient (37 years, male) was divided and 1) preincubated in 5% sheep blood broth in anaerobic condition at 37 °C; 2) blood culture bottle with stool filtered at 0,45 pm in anaerobic condition at 37 °C 3) preincubated in MRS medium in anaerobic condition at 37 °C; 4) preincubated in Trypticase Soy Broth medium in anaerobic condition at 37 °C; 5) 10 fold dilution sample was directly plated onto Columbia blood agar media, selective enterococcal, streptococcal, lactobacillus, bifidobacteria, enterobacteria media as well as preincubated for 12 h samples. After 24-72 h of incubation bacteriological studies were performed including observation, single colonies selection and microscopy. Isolated colonies were transferred to a new media to obtain pure cultures. After 24-72 h of incubation pure cultures were analyzed using PCR with species-specific primers, MALDI-TOF or 16S RNA sequencing. The strains with hemolytic activity were excluded at this point. The following species among others were obtained for the subsequent analysis: Bifidobacterium bifidum, Enterococcus casseliflavus, Enterococcus faecium (2), Enterococcus hirae, Lactobacillus crispatus, Lacticaseibacillus casei. Enterococci were tested using PCR for the absence of pathogenicity determinants listed above and antibiotic resistance genes. Enterococcus casseliflavus and one of Enterococcus faecium strains were excluded as carrying some of that genes. Bifidobacteria are generally regarded as safe. Lactobacilli were previously tested for hemolytic activity absence and were tested for antibiotic resistance genes absence. Bifidobacterium bifidum, Enterococcus faecium, Enterococcus hirae, Lactobacillus crispatus, Lacticaseibacillus casei were placed to cryobank for the particular patient and can be used at any time for the mono- or multiautoprobiotic drug preparation.

[0071] EXAMPLE 2. MULTIPLE AUTOPROBIOTIC STRAINS ISOLATION

[0072] A stool sample of an autistic child (8 years, male) was obtained. According to the gastroenterologist the child has been taking probiotic supplement based on Lactiplantibacillus plantarum for the previous 3 months. Also, bifidobacteria rates was too high in the stool analysis. The inventors were aimed to find all the indigenous enterococcal and lactococcal microbiota for the patient. The stool was divided and 1) preincubated in 5% sheep blood broth in anaerobic condition at 37 °C; 2) blood culture bottle with stool filtered at 0,45 pm in anaerobic condition at 37 °C 3) preincubated in MRS medium in anaerobic condition at 37 °C; 4) preincubated in Trypticase Soy Broth medium in anaerobic condition at 37 °C; 5) 10 fold dilution sample was directly plated onto Columbia blood agar media, selective enterococcal, streptococcal, lactobacillus, media as well as preincubated for 12 h samples. After 24-72 h of incubation bacteriological studies were performed including observation, single colonies selection and microscopy. Isolated colonies were transferred to a new media to obtain pure cultures. After 24- 72 h of incubation pure cultures were analyzed using PCR with species-specific primers, MALDI-TOF or 16S RNA sequencing. The strains with hemolytic activity were excluded at this point. The following species among others were obtained for the subsequent analysis: Enterococcus faecium, Enterococcus hirae, Enterococcus durans, Limosilactobacillus fermentum, Lacticaseibacillus casei. Enterococci were tested using PCR for the absence of pathogenicity determinants listed above and antibiotic resistance genes. All the strains were placed to cryobank for the patient and can be used at any time for the mono- or multiautoprobiotic drug preparation. According to this patient physician only monocomponent autoprobiotic is efficient for the patient so the patient gets the autoprobiotics one by one according to the doctor’s prescription based on the microbiota composition analysis.

[0073] EXAMPLE 3. AUTOPROBIOTIC STRAIN ISOLATION

[0074] A stool sample of a person (68 years, female) with multiple health conditions including food allergy was obtained. The patient was allergic to soy, milk, gluten. According to microbiota analysis the number of lactobacilli was decreased and patient desired to get lactobacillus based autoprobiotic. The sample was 1) preincubated in MRS medium in anaerobic condition at 37 °C and 2) was directly plated onto MRS agar plate. Preincubated samples were also plated onto MRS agar. After 48 h incubation under anaerobic conditions at 37 °C the mixed cultures on the plates were analyzed and pure cultures in another 48 h were obtained. Lacticaseibacillus rhamnosus, Limosilactobacillus reuteri, Limosilactobacillus fermentum were isolated and only L. fermentum demonstrated no hemolytic activity and no antibiotic resistance genes. L. fermentum was plated into oat milk and in 48 h the autoprobiotic liquid product based on L. fermentum oat milk was obtained. The strain was placed in cryobank for the storage.

[0075] EXAMPLE 4. LIQUID AUTOPROBIOTIC PREPARATION

[0076] In order to prepare liquid autoprobiotic (liquid fermented product) a single colony of patient’s culture was placed in 5 ml of sterile milk and incubated for 12-18 h. The product can be prepared on any animal or plant milk. After incubation 2% of starter culture was placed in 500-1000 ml of sterile milk and was incubated for another 12-18 h to achieve titratable acidity of 65-85°T and cell titre of 108- 109CFU / ml. After the autoprobiotic fermented product was tested for bacterial contamination the product was ready for the consumer. Packaged bottles shelf life is 14 days at 4°C. Multicomponent autoprobiotic was prepared by mixing in desired proportions two or more liquid products of fermentation by monocomponent autoprobiotic strains, which previously were tested for the absence of antagonism.

[0077] EXAMPLE 5. ENCAPSULATED AUTOPROBIOTIC PREPARATION In order to prepare encapsulated autoprobiotic a single colony of patient’s culture was placed in 5 ml of sterile milk and incubated for 12-18 h. The product can be prepared on any animal or plant milk. After incubation 2% of starter culture was placed in 500-1000 ml of sterile milk and was incubated for another 12-18 h to achieve fermentation with titratable acidity of 65-85°T and cell titre of 108-l 09CFU / ml. Fermented product was centrifuged, supernatant was removed, the cells were resuspended in dextrose-gelatin cryo-and lyo-protectant in a rate 1 :2. Quickly frozen samples was lyophilized according to the protocol for the bacterial cells. After the freeze drying and additional test for contamination and life bacterial titer count the autoprobiotic powder was encapsulated using sterile encapsulator device. Encapsulated autoprobiotic preparation was tested for contamination and then it was ready for the consumer. Packaged capsules shelf life is 1 year at 4-25°C. Multicomponent encapsulated autoprobiotic was prepared by mixing in desired proportions of two or more ready monocomponent autoprobiotics powders before the capsulation. The strains used for the creation of multicomponent autoprobiotic were tested for the cultures not to have antagonism against each other.

[0078] EXAMPLE 6. ENCAPSULATED VAGINAL AUTOPROBIOTIC PREPARATION

[0079] A vaginal sample of a healthy woman (38 years) was directly plated on MRS agar and was incubated for 48 h at 37 °C in 5% CO2. The mixed culture was observed after the incubation with a domination of one strain. 5 single colonies of different morphology were taken onto new sterile MRS plates in order to get pure cultures. New plates were incubated under the same conditions and in 48 h pure cultures were obtained. After the microscopy the bacilli (n=3) were taken for further exams. The strains were identified by 16s RNA sequencing. Predominant strain L. crispatus and two other lactobacilli strains with the lack of antibiotic resistance genes and hemolytic activity had been put in cryobank storage. In a two months the patient got the encapsulated vaginal autoprobiotic preparation right before the planned antibiotic therapy in order to restore microbiota during the drug administration. All three strains are stored in cryobank under -80 °C and available as long as patient wants it.

[0080] EXAMPLE 7. PREPARATION OF AUTOPROBIOTIC BASED ON INDIGENOUS CONSORTIUM

[0081] A functional personified microbial product based on Indigenous Consortium (IC) was prepared using patients’ fecal samples. Samples of 50 mg feces (previously frozen -80 °C) were transferred into 10 mL of thioglycol medium (PDB, Conda-Pronadisa Laboratories, Madrid, Spain) with addition of 250 pL of 40% sterile glucose solution and 5 pL of vicasol (Joint Stock Company DALKHIMPHARM, Khabarovsk, Russia), then mixed in the lower part of the test tube and throughout the volume of the medium. The tubes were placed at 37 °C for 6 days. Inoculation of IC occurred in 10 mL of medium protein-vitamin soy product Supro Plus 2640 (Monsanto company, Missouri, United States, concentration of 40 g / L), 1 mL of the consortium was centrifuged (MiniSpin centrifuge (Eppendorf)) for 15 min at 3.5 thousand rpm, then supernatant was discarded and 10 mL of Supro Plus 2640 were added to the sediment and were mixed. The samples were incubated at 37 °C under anaerobic conditions for 1 day. Then, 7 mL of the fermented product were added to the 1 L of Supro 2640 and were incubated for 48-56 h at 37 °C. Final personified IC products were tested by bacteriological method and qPCR. Exclusion criterion for admission was the presence of pathogenic or opportunistic bacteria.

[0082] The IC were prepared from 44 samples. However, after their bacteriological examination and using qPCR, elevated levels of Clostridium difficille, C. perfringens, Proteus spp., Enterobacter spp., and Candida albicans were detected in 8 samples. These samples were regarded as contaminated and dangerous and were not used for clinical studies. A comparative study of the IC and fecal samples content was also performed using qPCR and metagenome analysis.

[0083] Monostrain autoprobiotcs allowing the genome study of the bacteria used for microbial therapy seems the least dangerous but they are good for the recipients with relatively developed microbiota, which need proper microbiota modulation. In the metabolic syndrome study, the inventors were evaluating another approach of making autoprobiotics based on fecal microbiota cultivation outside the host on selective media for several days. After 6 days of cultivation of the indigenous bacteria microbiota richness decreased to a certain degree but still it was represented by about 30 bacterial families with predominance of lactobacilli. The decrease in anthropometric parameters of obesity, liver enzyme level correction, reduction in C reactive protein and triglyceride concentrations were revealed after use of IC. The decrease in genera Bifidobacterium, Enterobacter, Paraprevotella, and Prevotella, as well as the increase in Bacteroides fragilis and Oscillospira spp. populations were shown after consumption of IC. A negative correlation between the quantity of B. fragilis and the anthropometric parameters of obesity (r = -0.48) and C reactive protein level (r = -0.36) in serum was established. EXAMPLE 8. TREATMENT OF PATIENTS WITH IRRITABLE BOWEL SYNDROME BY CORRECTION OF DYSBIOTIC DISORDERS USING AUTOPROBIOTICS

[0084] I. Preliminary assessment of gut microbiota characteristics in healthy subjects and patients with IBS

[0085] MA TERIALS AND METHODS

[0086] Human subjects

[0087] Fecal samples of ten healthy volunteers and ten patients with Irritable Bowel Syndrome (IBS) (18-75 years old) were analyzed for pathogens inducing intestinal infections using bacteriological and immunochromatographic tests. Further, fecal samples from healthy people and patients suffering from IBS were examined by bacteriological method and metagenome analysis.

[0088] Gut microbiota study

[0089] Bacteriological method for analysis of intestinal microbiota. The quantity of viable bacteria (CFU / g) in feces was determined by inoculation of the corresponding tenfold serial suspension dilutions on a number of selective solid nutrient media in Petri dishes and evaluation of the grown colonies of bacteria after incubation at 37 °C for 24 hours. For counting different genera of marker microorganisms at once such as E. coli. Enterococcus spp., Klebsiella spp., Proteus spp., Enterobacter spp. chromogenic selective media were used (Pronadisa 1424, Spain; HiCrome Coliform Agar, India). To determine the number of lactobacilli inoculation was carried out on Pronadisa 1043 Agar MRS medium (Spain), followed by cultivation in an anaerobic culture apparatus (Thermo Scientific AN0025A, USA) at 37 °C for 48 hours.

[0090] Genetic method. DNA was isolated from feces using DNA-express kit "LITEKH" (Moscow, Russia). To study the intestinal metagenome, libraries of variable regions V3 and V4 of 16S RNA gene analyzed using a MiSeq sequencing device (Illumina, USA). These sites provide the most accurate data on the quantitative and qualitative composition of microbiome. The libraries were prepared using the standard method based on two rounds of PCR. The first round is amplification of the fragment of 16S RNA gene and addition of adapter nucleotide sequences to the target fragment using PCR primers presented in Table 1. The second round of PCR, subsequent sample preparation, sequencing and bioinformatic data processing were carried out at “Biobank” Resource Center of Saint-Petersburg State University (St. Petersburg, Russia).

[0091] Table 1. The sequences of primers used for analysis of 16S rRNA gene.

[0092] Bioinformatic analysis. On the basis of lattice and ggplot2 modules of the R-software package, tools for visualizing the composition of microbiome obtained by sequencing V3 / V4 regions of 16S rRNA have been implemented. The resulting tools make it possible to demonstrate the bacterial representation of the microbiome, and further provide the possibility of grouping different samples (for example, belonging to the same study group). Based on lattice module of the R-software package, a module for visualizing the representation vectors of microorganisms in projections on the principal component axes has been developed. The developed module allows visually selecting sets of samples belonging to the same study group. On the basis of ggplot2 module of the R-software package, a module for creating dendrograms of hierarchical clustering of sample representation vectors at different distances has been developed.

[0093] RESULTS

[0094] Bacteriological study

[0095] When analyzing the results of the bacteriological study, it was shown that patients with IBS were characterized by the presence of atypical Escherichia coH. increase in Klebsiella pneumoniae and Proteus vulgaris content and decrease in lactobacilli content (Fig. 1). Grey lines in Fig.l indicate the average amount of specified bacteria in healthy people compare to black lines describing the patients with IBS.

[0096] Metagenomic analysis Figures 2, 3 and 4 demonstrate percentage ratio of specific microbiota representatives at the level of phyla, families and genera. The analysis carried out in respect of phyla has shown that fecal samples of patients with IBS are characterized with decreased content of Bacteroidetes and increased content of Firmicutes, Actinobacteria and Proteobacteria. Arrows indicate the decrease and increase of specified bacteria in IBS patients in compare to healthy people.

[0097] The percentage ratio of the families Enterobacteraceae and Desulfovibtrionaceae (capable of destroying enterobacteria), Veilonellaceae (reducing the amount of lactic acid), pathogenic gram-positive bacteria such as Streptococcaceae, Erysipelotrichaceae in IBS patients was increased. At the same time, the feces of healthy people contained more commensals from the families Prevotelaceae, Puminococcaceae. Bacleroidaceae. associated with important metabolic functions in the gut, e.g. taking part in protein, fat and carbohydrate metabolism and vitamin synthesis (Fig. 3).

[0098] Further, it was shown that the intestine of healthy people has a significantly increased content of the genera Coprococcus. Blautia, Bilophila, Sutterella whose functions are not fully understood currently, an Faecalibacterium - butyrate-producing commensals positively affecting intestinal motility, mucus formation and having immunomodulatory properties (Fig. 4). In Figure 4 healthy people group is indicated in grey and IBS patients group is indicated in black.

[0099] II. Preclinical studies: experimental assessment of autoprobiotic treatment in rats with induced dysbiosis

[0100] MA TERIALS AND METHODS

[0101] The study of the efficacy and safety of probiotic therapy was carried out on 12 healthy male Wistar rats with induced dysbiosis. Rats were randomized into 3 groups:

[0102] (1) 1stgroup (4 animals) was administered 0.5 ml of lactic-acid starter culture containing 5.5 x 108CFU / ml Enterococcus faecium L5 (genetic derivative of E.faecium L3 probiotic culture with erythromycin resistance genes - “Laminolact”, “Avena” LLC (St. Petersburg, Russia); preparation is disclosed, e.g. in patent publication RU 2227039

[0027] , incorporated herein by reference in its entirety);

[0103] (2) 2ndgroup (4 animals) received lactic-acid starter culture containing 108CFU / ml of indigenous Enterococcus faecium (starter culture preparation is described in section IV of Example 8); (3) 3rdgroup (4 animals) received 0.5 ml of milk.

[0104] In the course of the study, appetite, weight, stool characteristics and behavior of laboratory animals were monitored. Microbiological examination of feces was carried out on the 1stand 8thdays of the study. Prior administration of indigenous enterococci strains they were genetically identified and analyzed in respect of pathogenic determinants by PCR method.

[0105] RESULTS

[0106] The results of the study have shown that rats treated with an autoprobiotic were characterized by earlier normalization of weight, stool and appetite (3rdday) compared to rats receiving Enterococcus faecium L3 (5thday).

[0107] The analysis of microbiological data has demonstrated: (1) a statistically significant increase of lactobacilli content in the group treated with autoprobiotics (from 5.17 ± 0.7 to 7.0 ± 0.27 1g CFU; p<0.01); (2) a significant increase of bifidobacterium species in the group receiving autoprobiotic therapy (from 4.0 ± 0.89 to 6.0 ± 0.26 1g CFU); (3) a decrease of opportunistic flora content in groups 1 and 2.

[0108] III. Clinical studies: experimental assessment of Enterococcus faecium autoprobiotic safety in healthy volunteers

[0109] MA TERIALS AND METHODS

[0110] The safety of an autoprobiotic product based on Enterococcus faecium was studied in 10 healthy volunteers. In the course of the study, particular clinical scores including appetite, stool characteristics, dyspeptic disorders, temperature, general well-being were monitored, as well as laboratory results such as hematological parameters, markers of liver, kidney and pancreas function. Microbiological examination of feces was further carried out.

[0111] The subjects received 50 ml of lactic-acid starter culture twice a day containing 108CFU / ml of indigenous Enterococcus faecium in 1 ml of starter for 10 days. Starter culture preparation described in section IV of Example 8.

[0112] RESULTS The results of the clinical study have not revealed any negative manifestations or adverse effects following autoprobiotic therapy based on indigenous Enterococcus faecium. Furthermore, all subjects reported good organoleptic properties (taste, texture, color) of the product.

[0113] IV. Clinical studies: assessment of Enterococcus faecium autoprobiotic efficacy in IBS patients and its use in clinical practice

[0114] MA TERIALS AND METHODS

[0115] Human subjects

[0116] The efficacy of an autoprobiotic product based on Enterococcus faecium was studied in patients suffering from Irritable Bowel Syndrome (IBS). 50 patients with IBS (22-55 years old) were examined. They were randomly divided into 2 groups:

[0117] (1) 1stgroup (25 patients) received twice a day 50 ml of lactic-acid starter culture containing 108CFU / ml of indigenous Enterococcus faecium in 1 ml of starter for 10 days;

[0118] (2) 2ndgroup (25 patients) twice a day received 50 ml of lactic-acid starter culture containing 108CFU / ml of Enterococcus faecium L3 for 10 days.

[0119] Assessment the effect of probiotic therapy on clinical symptoms of IBS was carried out in respect of abdominal pain, epigastric discomfort, flatulence, stool characteristics according to Bristol Scale. Further, the study has encompassed the possible effects of probiotic treatment on appetite and general well-being of the patients based on their subjective sensation.

[0120] Starter cultures preparation

[0121] Starter cultures were based on the probiotic strain E. faecium L3 or indigenous enterococci of a patient to be treated. Preparation of starter cultures is disclosed, e.g. in patent publications RU 2460778

[0011] and RU 2546253

[0014] , incorporated herein by reference in its entirety.

[0122] To isolate autoprobiotic enterococci from fecal samples 1 g of biomaterial was added to 9 ml of sterile phosphate buffer (pH 7.4). 100 pl of feces suspension at a dilution of 1 : 10 was inoculated on a selective medium for enterococci (Enterococcus selective agar, Conda, Spain). Cultivation was carried out at 37 °C for 24-48 hours. As a result, it is possible to provide preliminary identification of enterococci species. Figure 5 demonstrates growth of enterococci on chromogenic and azide media. As a result, three isolated clones of enterococci corresponding by their cultural characteristics to Enterococcus faecium were obtained.

[0123] The identification of individual colonies was carried out based on morphological and microscopic characteristics. Three individual colonies typical of Enterococcus faecium were selected and inoculated on a new Petri dish with solid medium for obtaining pure cultures. Cultivation was carried out at 37 °C for 24 hours. Microscopic preparations of pure cultures were stained according to Gram’s method for further identification. Then, pure cultures of the identified bacteria were analyzed by genetic methods.

[0124] To assess molecular genetic characteristics of the selected enterococci strains chromosomal DNA was isolated followed by PCR analysis for species identification and pathogenic determinants detection. For express DNA isolation a pure bacterial culture from a Petri dish (5- 10 colonies) was suspended in 50-100 pl of sterile distilled water and boiled for 10 minutes followed by centrifugation at 8000 rpm. The supernatant containing bacterial DNA was used for PCR (30 cycles at annealing temperature of 57 °C). The unique primers for identification of Enterococcus species and its pathogenic genes (Table 2) were constructed in the computer program BLAST

[0028] , It allows isolating non-pathogenic strains for further obtaining a safe product.

[0125] Detection of PCR results was carried out by electrophoresis in 1 % agarose gel. Accordingly, for preparation of autoprobiotics, bacterial clones belonging to Enterococcus faecium (the product of 658 b.p. in Table 2) lacking any pathogenic determinants were selected.

[0126] The selected genetically safe strains of enterococci without pathogenic genes were inoculated on 10 ml of milk (1.5 %, autoclaved at 120 °C for 20 min) and incubated at 37-42 °C for 24-48 hours until milk fermentation. 10 ml of starter culture was further used as inoculum to produce a larger volume of the product. For said purpose, 10 ml of starter culture was inoculated per 1 liter of sterile milk heated at 37 °C and incubated at 37-42 °C for 24-48 hours until milk fermentation. Culture contamination was tested by incubation of 100 pl of starter culture on tryptose agar (“Ferak”, Germany) at 37 °C for 24 hours. Optionally, samples of obtained strains with the required set of characteristics in the form of pure starter cultures were frozen and kept in a cryobank at -75 °C for up to a year. Table 2. DNA sequences of primers and size of PCR products for detection of species and pathogenic determinants of enterococci.

[0127] RESULTS

[0128] The results of monitoring survey following probiotic therapy have shown a significant improvement in all clinical parameters in both groups. At the same time, the dynamics of several parameters between two comparison groups was characterized by statistically significant differences. In particular, the group of patients receiving an autoprobiotic was reported as having a decrease in severity of flatulence manifestation associated with excessive growth of opportunistic microflora. The dynamics of the said parameter in the autoprobiotic group varied from 2.45 ± 0.12 to 0.62 ± 0.16 scale score vs 2.33 ± 0.11 and 1.33 ± 0.17 scale score in the group treated with Enterococcus faecium L3.

[0129] Furthermore, as a result of autoprobiotic treatment the severity of IBS symptoms has also been mitigated including abdominal pain (0.41 ± 0.15 vs 0.87 ± 0.15 scale score in the Enterococcus faecium L3 group) and abdominal discomfort (0.37 ± 1.14 vs. 0.79 ± 1.17 scale score).

[0130] The results of microbiological study of the gut microbiota state have shown that both groups were characterized by statistically significant improvements after probiotic / autoprobiotic treatment. However, more clinically meaningful results were associated with autoprobiotic therapy, namely:

[0131] 1) a statically significant decrease in opportunistic enterobacteria content (from 0.87 ± 0.38 to 0.12 ± 0.12 scale score, p = 0.04);

[0132] 2) a statically significant increase in bifidobacterium content (from 7.79 ± 0.28 to 8.95 ± 0.04 scale score, p = 0.0009);

[0133] 3) a statically significant increase in lactobacilli content (from 7.83 ± 0.21 to 8.95 ± 0.04 scale score, p = 0.0007);

[0134] 4) a statically significant increase in enterococci content (from 4.91 ± 0.11 to 5.83 ± 0.20 scale score, p = 0.002);

[0135] 5) a statically significant increase in E. coli content (from 6.12 ± 0.19 to 6.41 ± 0.17 scale score, p = 0.005).

[0136] Thus, the results of the study have shown that autoprobiotic therapy based on indigenous strains of Enterococcus faecium is an original, effective and safe approach for treatment of dysbiosis of any etiology, inter alia, in IBS patients.

[0137] EXAMPLE 9. NORMALIZATION OF IMMUNITY, MICROBIOTA AND FUNCTION OF THE GASTROINTESTINAL TRACT IN PATIENTS WITH PARKINSON’S DISEASE USING PROBIOTICS

[0138] The study of the effect of probiotics on the course of the disease as well as cytokine status and activity of digestive enzymes was carried out in patients with Parkinson’s disease (PD). Further, the study has encompassed the possible effects of indigenous enterococci (autoprobiotics) on clinical symptoms of PD, microbiota composition, cytokine status and activity of digestive enzymes.

[0139] MA TERIALS AND METHODS

[0140] Human subjects 40 patients with Parkinson's disease (56.6-77 years old) and 10 healthy volunteers (40-67 years old) were examined. Patients with Parkinson's disease receiving basic therapy were divided into two groups: (1) “Probiotic” - 20 patients (9 women, 11 men, 66.63 ± 10.1 years old) were administered a probiotic in the form of a starter culture based on E. faecium L3 for 10 days; (2) “Autoprobiotic” - 20 patients (16 women, 4 men, 63.84 ± 8.78 years old) received an autoprobiotic. Starter cultures based on the probiotic strain E. faecium L3 or indigenous enterococci were prepared by “Microbiome” LLC (St. Petersburg, Russia). Patients received twice a day 50 ml of starter culture containing 5 x 108CFU / ml of enterococci for 20 days.

[0141] In all patients, the severity of non-motor manifestations of PD was assessed using diagnostic scales: Unified PD Rating Scale (UPDRS), Part 2; PD Non-Motor Symptoms Scale (PD NMS); Bristol Stool Scale; Scale for Evaluating Gastrointestinal Function Disorders in Patients with PD. In addition, patients kept a diary of health state indicating the frequency of defecation, stool characteristics and subjective sensation. The detailed clinical examination was performed before, during (to exclude the occurrence of side effects) and after probiotic / autoprobiotic therapy.

[0142] Samples collection and handling

[0143] Feces from 40 patients were collected before and after probiotic and autoprobiotic therapy. 80 fecal samples within 8-12 hours after defecation were delivered to the laboratory for bacteriological study. The other 80 fecal samples were frozen and stored at -20 °C for further analysis by real-time PCR. All patients before and after probiotic administration were taken blood tests. The content of pro- and anti-inflammatory cytokines was determined in blood serum (58 samples). To study the effect of the probiotic on the activity of digestive enzymes (alkaline phosphatase, aminopeptidase and maltase) in PD patients, fecal samples were examined twice before and after administration of the starter culture. In healthy volunteers (10 subjects), samples of feces and blood were taken in a single step.

[0144] Starter cultures preparation

[0145] Starter cultures were based on the probiotic strain E. faecium L3 or indigenous enterococci of a patient to be treated. Preparation of starter cultures is described in section IV of Example 8.

[0146] To isolate autoprobiotic enterococci from fecal samples 1 g of biomaterial was added to 9 ml of sterile phosphate buffer (pH 7.4). 100 pl of feces suspension at a dilution of 1 : 10 was inoculated on a selective medium for enterococci (Enterococcus selective agar, Conda, Spain). Cultivation was carried out at 37 °C for 24-48 hours. As a result, it is possible to provide preliminary identification of enterococci species.

[0147] The identification of individual colonies was carried out based on morphological and microscopic characteristics. Three individual colonies typical of Enterococcus faecium were selected and inoculated on a new Petri dish with solid medium for obtaining pure cultures. Cultivation was carried out at 37 °C for 24 hours. Microscopic preparations of pure cultures were stained according to Gram’s method for further identification. Then, pure cultures of the identified bacteria were analyzed by genetic methods.

[0148] To assess molecular genetic characteristics of the selected enterococci strains chromosomal DNA was isolated followed by PCR analysis for species identification and pathogenic determinants detection. For express DNA isolation a pure bacterial culture from a Petri dish (5- 10 colonies) was suspended in 50-100 pl of sterile distilled water and boiled for 10 minutes followed by centrifugation at 8000 rpm. The supernatant containing bacterial DNA was used for PCR (30 cycles at annealing temperature of 57 °C). The unique primers for identification of Enterococcus species and its pathogenic genes (Table 2) were constructed using BLAST

[0028] , It allows isolating non-pathogenic strains for further obtaining a safe product.

[0149] Detection of PCR results was carried out by electrophoresis in 1 % agarose gel. Accordingly, for preparation of autoprobiotics, bacterial clones belonging to Enterococcus faecium (the product of 658 b.p. in Table 2) lacking any pathogenic determinants were selected.

[0150] The selected genetically safe strains of enterococci without pathogenic genes were inoculated on 10 ml of milk (1.5 %, autoclaved at 120 °C for 20 min) and incubated at 37-42 °C for 24-48 hours until milk fermentation. 10 ml of starter culture was further used as inoculum to produce a larger volume of the product. For said purpose, 10 ml of starter culture was inoculated per 1 liter of sterile milk heated at 37 °C and incubated at 37-42 °C for 24-48 hours until milk fermentation. Culture contamination was tested by incubation of 100 pl of starter culture on tryptose agar (“Ferak”, Germany) at 37 °C for 24 hours. Optionally, samples of obtained strains with the required set of characteristics in the form of pure starter cultures were frozen and kept in a cryobank at -75 °C for up to a year.

[0151] Gut microbiota study Bacteriological method for analysis of rat intestinal microbiota. The quantity of viable bacteria (CFU / g) in feces was determined by inoculation of the corresponding tenfold serial suspension dilutions on a number of selective solid nutrient media in Petri dishes and evaluation of the grown colonies of bacteria after incubation at 37 °C for 24 hours. For counting different genera of marker microorganisms at once such as E. coH, Enterococcus spp., Klebsiella spp., Proteus spp. , Enter obacter spp. chromogenic selective media were used (Pronadisa 1424, Spain; HiCrome Coliform Agar, India). To determine the number of lactobacilli inoculation was carried out on Pronadisa 1043 Agar MRS medium (Spain), followed by cultivation in an anaerobic culture apparatus (Termo Scientific AN0025A, USA) at 37 °C for 48 hours.

[0152] Real-time PCR. To isolate DNA, 0.025-0.030 g of stool was added to 200 pl of the lysis solution from DNA-express kit "LITEKH" (Moscow, Russia), homogenized using Microspin vortex, and the mixture was incubated at a temperature of 98 °C for 30 min. The samples were then centrifuged for 90 sec at 13.4 thousand rpm (Mini-Spin Centrifuge, Eppendorf). Further, 60 pl of the supernatant was added to a tube containing 100 pl of the lysis solution. Then, the mixture was again incubated for 10 min at 98 °C. After that, the tubes were vortexed and centrifuged for 75 sec at 13.4 thousand rpm. The isolated DNA was stored at temperatures 0-40 °C and used for real-time PCR.

[0153] Real-time PCR with Taqman fluorescently labeled probes was performed on Bio-Rad device using Opticon Monitor 3 software. PCR was carried out with “Colonoflor-16” reagent kit (AlfaLab LLC, Russia), following the manufacturer's instructions. The kit allows to identify and quantify the obligate and opportunistic representatives of microbiota: Lactobacillus spp., Bifidobacterium spp., Clostridium difficile, Enterococcus spp., Escherichia coli, Escherichia coli enter opathogenic, Bacteroides fragilis, Bacteroides thetaiotaomicron, Faecalibacterium prausnitzii, Proteus mirabilis / vulgaris, Staphylococcus aureus, Klebsiella pneumoniae, Klebsiella oxytoca, Candida spp., Clostridium perfringens, Proteus spp., Enter obacter spp., as well as the total number of bacteria.

[0154] 16S RNA gene sequence analysis. To study the intestinal metagenome, libraries of variable regions V3 and V4 of 16S RNA gene were analyzed using a MiSeq device (Illumina, USA). These sites provide the most accurate data on the quantitative and qualitative composition of microbiome. DNA was isolated from feces using DNA-express kit "LITEKH" (Moscow, Russia) according to the above described technique. The libraries were prepared using the standard method based on two rounds of PCR. The first round is amplification of a fragment of 16S RNA gene and addition of adapter nucleotide sequences to the target fragment using PCR primers presented in Table 1. The second round of PCR, subsequent sample preparation, sequencing and bioinformatic data processing were carried out at “Biobank” Resource Center of Saint- Petersburg State University (St. Petersburg, Russia).

[0155] Study of cytokine status

[0156] The cytokine status was assessed by examining the blood serum of patients before and after probiotic / autoprobiotic therapy for the content of ILip, IL4, IL6, IL10, IL18, IFN-y, TNF-a. The analysis was carried out using kits for enzyme immunoassay (ELISA) (JSC Vector-Best, Russia).

[0157] Assessing activity of key digestive enzymes

[0158] A number of enzymes involved in the final stages of hydrolysis of phosphoric acid esters (alkaline phosphatase), carbohydrates (maltase and amylase) and proteins (aminopeptidase) were studied. Enzyme activity was assessed by standard techniques known in the art.

[0159] Statistical analysis

[0160] Statistical analysis was performed in the program Statistica for Windows, v. 10 (StatSoft, USA) using parametric and nonparametric criteria. For each group descriptive characteristics were calculated such as feature frequency (for discrete features), mean value (M), standard deviation (c), error of mean (m), minimum, maximum, median value and quartiles for features with a continuous distribution. The results were considered statistically significant at p < 0.05. Statistical processing of data on the concentration of microorganisms in feces was performed after a preliminary logarithmic transformation of the initial values. Statistical significance was assessed using the Kruskal -Wallis A-test for non-parametric data. Graphs and diagrams were built in Statistica for Windows, Excel, GraphPadPrism.

[0161] RESULTS

[0162] Clinical symptoms

[0163] The group of patients receiving a probiotic was reported as having a decrease in severity of vegetative manifestations, namely, shortening of the interval between defecations (100 %), reducing or disappearing of nausea after meal (90 %), decreasing of abdominal discomfort (85 %) and weakness (75 %). The average frequency of defecations before and after probiotic and autoprobiotic therapy is demonstrated on Figure 6. It shows an increase in the number of defecations, which was previously reduced in almost all patients. An improvement in stool characteristics according to Bristol Scale was further reported after treatment. At that, there weren’t any statistically significant differences in the neurological status of patients before and after probiotic and autoprobiotic therapy. However, comparison of non-motor symptoms according to PD NMS scale has shown a tendency to their reduction / disappearance (Fig. 7).

[0164] Effect of probiotics on gut microbiota in PD patients

[0165] Results of bacteriological study. Previously, the ability of autoprobiotic enterococci to reduce the number of atypical Escherichia and the tendency to displace the population of Proteus, Citrobacter and other opportunistic enterobacteria has been demonstrated by primary (before the autoprobiotic admission) and secondary (after the treatment) studies (Fig. 8). Further, the results of assessing the diversity of gut microbiota in healthy volunteers were compared with those for PD patients (before and after probiotic and autoprobiotic therapy). The bacteriological study has shown an increase in enterococci content following probiotic and indigenous enterococci administration and a decrease in Proteus content before and after autoprobiotic treatment (Fig. 9).

[0166] Real-time PCR study results.

[0167] The results of assessing the diversity of gut microbiota in healthy volunteers were compared with those for PD patients (before and after probiotic and autoprobiotic therapy). The real-time PCR analysis has shown a statistically significant increase in enterococci content following probiotic and indigenous enterococci administration, a tendency towards an increase in Proteus content following the probiotic treatment, an increase in the amount of Escherichia and Klebsiella, as well as Clostridium difficile and C. perfringens (Fig. 10). The arrows indicate the microbiota composition more significant changes.

[0168] Metagenomic analysis results. The results of microbiome study (16S rRNA) in healthy volunteers and PD patients before and after autoprobiotic treatment were studied are shown for the phylum and family level. The results of assessing the diversity of bacteria relating to different taxonomic groups have shown a statistically significant decrease in Bacteroides content and its partial recovery following probiotic treatment. Further, a tendency towards an increase in the amount of Lachnospiraceae family and a decrease of fusobacteria content has also been reported after probiotic therapy.

[0169] The representation of the group proximity degree was obtained by comparing groups using PCI (Fig. 11, 12) and alpha-diversity analysis (Fig. 13).

[0170] Figures 11 and 12 demonstrate the results of PCA analysis with two variants of markers representing the mean values and taking into account data from the gut metagenome of a particular subject. The results further demonstrate well-separated clusters for samples from PD patients differing from control group samples (healthy volunteers), which are located somewhere between these clusters before and after therapy. In general, gut microbiota of PD patients has not significantly changed after autoprobiotic therapy. Mainly, specific changes varied between individuals and were reported as non-significant variations within groups, however, having the same trend of approximation with a control group of healthy subjects after autoprobiotic treatment.

[0171] The results of PCA analysis revealed that each individual before and after treatment were closely located (Figs. 11 and 12). On the other hand, it is preferable to reveal the area corresponding to healthy gut microbiota in order to understand current trends, their intensity and significance.

[0172] By means of alpha-diversity analysis (Fig. 13), a tendency demonstrating the recovery of said parameter has been shown after autoprobiotic administration.

[0173] Effect of probiotics on activity of key digestive enzymes

[0174] For assessing activity of key digestive enzymes (alkaline phosphatase, aminopeptidase, a- amylase and maltase) in PD patients, fecal samples were examined twice before and after autoprobiotic therapy (29 samples in total: 20 samples from female patients, 9 samples from male patients). It was shown, that the activity of a-amylase decreased in the female group following the therapy: 1.69 mg / min / g of tissue after autoprobiotic treatment vs 2.32 mg / min / g of tissue before autoprobiotic treatment (the difference is significant, p < 0.05). Further, a downward trend in the activities of maltase and aminopeptidase has also been reported. Any statistically significant changes in alkaline phosphatase activity in the female group have not been found. The male group was reported as not having enzyme activity variations following autoprobiotic treatment. The results of the study are presented on Figure 14.

[0175] Thus, the discussed example encompasses the study of gut microbiota composition variations, activity of key digestive enzymes in PD patients administered an autoprobiotic for 20 days. The effectiveness of said therapy has been demonstrated resulting in a partial but significant restoration of the main parameters of the gut microbiota followed by normalization of intestinal motility, evacuation properties of the intestine, macroscopic changes of stool in accordance with Bristol Scale and changes in the activity of digestive enzymes.

[0176] EXAMPLE 10. USE OF AUTOPROBIOTICS FOR CORRECTION OF DYSBIOSIS IN CANCER PATIENTS.

[0177] Long-term observation, study and correction of the state of intestinal microbiota in cancer patients in the long-term period after undergoing radical surgery.

[0178] MA TERIALS AND METHODS

[0179] Human subjects

[0180] 28 patients with colorectal cancer after surgery who received autoprobiotics in the perioperative period.

[0181] Correction of dysbiotic disorders was carried out using autoprobiotics based on Enterococcus faecium after radical operations in the perioperative period. In order to diagnose the state of the microbiota before and after therapy, the real-time PCR method was carried out using “Colonoflor-16” reagent kit (AlfaLab LLC, Russia). The patients received a course of liquid autoprobiotics of 50 ml twice a day for 20 days.

[0182] RESULTS

[0183] The results of the studies have shown that patients with colorectal cancer have severe dysbiosis, which worsens after surgical treatment. The use of autoprobiotics resulted in a decrease in the content of opportunistic bacteria and an increase in the content of bacteria relating to the normal microbiota. However, in the long-term period - 1,5 to 2 years after the surgeries, dysbiotic disorders were found in these patients, but less marked than in the period before the first use of autoprobiotics. Second course of autoprobiotics improved the state of intestinal microbiota, which was accompanied by an improvement in health of patients.

[0184] Patient No. 1, 62 years old. Diagnosis: Sigmoid colon cancer T3N2aM0G2. Disease complication: perforation of the diverticulum of the descending colon. Local limited peritonitis. Concomitant diseases: colonic diverticulosis, stage 1 hypertension, dislipidemy.

[0185] The patient had a colostomy for 1.5 years after radical surgery, a second surgery to restore the passage and function of the intestine was performed in October 2019, after which the patient went to work in his specialty (construction worker, heavy physical labor for 8-10 hours a day). The patient has no complaints, notes the good tolerance of the probiotic, and good health after the first and second courses. In general, on a 7-point scale, the patient evaluates health and quality of life as 7. Analysis of the normal microbiota composition of patient No. 1 has revealed a decrease for lactobacilli (Lactobacillus spp.) during the entire observation period, a significant decrease for Escherichia coli before the first course of autoprobiotic and its recovery after the course. Attention is drawn to the presence of opportunistic Enterobacter spp. in a significant amount before the first course of the autoprobiotic (108CFU / g) and its absence after the course of the autoprobiotic; and the presence of pathogenic Fusobacterium nucleatum in a significant amount before the first course (108CFU / g), its complete disappearance after the course in the perioperative period, and its absence in the long-term period.

[0186] Patient No. 2, 83 years old. Diagnosis: Cecum cancer T3NlbM0G2. Major concomitant diseases: stage 2 hypertension, condition after aortic valve replacement 6 years ago.

[0187] The patient notes the good tolerance of the autoprobiotic, and rapid recovery of the intestines after surgery. In the long-term postoperative period, there were constipations, which significantly decreased after a second course of autoprobiotics. The patient expressed a desire to repeat the course of the autoprobiotic. The remaining complaints of general weakness, fatigue, shortness of breath and poor tolerance of moderate physical exertion are mostly due to concomitant diseases. In general, on a 7-point scale, the patient evaluates health and quality of life as 3. Analysis of the normal microbiota composition of patient No. 2 has shown that before both courses of the autoprobiotic, the amount of Lactobacillus spp. was reduced, which increased from 104CFU / g to 4- 105CFU / g after the second course, and the amount of Bifidobacterium spp. during the entire observation period was 107CFU / g. The amount of Escherichia coli was reduced in the long-term period to 4 105CFU / g; the amount of Bacteroides fragilis group was sharply reduced after the first course of the autoprobiotic, but fully recovered in the long-term period, and the amount of Bacteroides thetaiotaomicron was reduced during the entire observation period to 108CFU / g. Attention is drawn to the presence of opportunistic Enterobacter spp. in a significant amount before the first course of the autoprobiotic (106CFU / g) and its complete absence in the long-term postoperative period both before and after the second course of the autoprobiotic.

[0188] EXAMPLE 11. PERSONALIZED PROBIOTIC THERAPY FOR GASTRITIS ASSOCIATED WITH HELICOBACTER PYLORI.

[0189] Evaluation of the protective effect of autoprobiotics in monotherapy in patients with gastritis, gastric and duodenal ulcers associated with Helicobacter pylori.

[0190] MA TERIALS AND METHODS

[0191] Human subjects

[0192] 31 patients with Helicobacter pylori carriage. According to the results of FGDS, the following diagnoses were reflected in the conclusions: 22 (71%) patients had gastritis, 6 (19.3%) patients had gastric cancer, in one case (3.2%) a gastric ulcer was diagnosed, and in one case (3.2%) erosive gastritis was diagnosed. One patient (3.2%) had no pathology.

[0193] Monotherapy with autoprobiotics for patients with diseases associated with Helicobacter pylori was carried out once. The patients received a course of liquid autoprobiotics of 50 ml twice a day for 20 days. The infection and control of the effectiveness of treatment of Helicobacter pylori were detected using an invasive biochemical method (AMA RUT Reader), as well as fecal examination by immunochromatographic method (H&R H. pylori Vegal Farmaceutica S.L., Spain) in 2 months after the end of the therapy.

[0194] RESULTS

[0195] Monotherapy with autoprobiotics was successful, as evidenced by disappearance of symptoms of dyspepsia and eradication of the pathogen in 82% of patients (p<0.05). Patient No. 1, 27 years old. Diagnosis: chronic HP-associated gastritis, exacerbation.

[0196] Consultation 1. The patient complained of severe pain in the upper abdomen, frequent heartbum, belching of sour and bitter, pain in the abdomen on an empty stomach, nausea, rumbling in the abdomen, a feeling of distension and fullness, bloating, gas passing through the intestines, which is accompanied by a decrease in feeling bloating, alternating unformed and hard stools, a feeling of incomplete emptying of the intestine.

[0197] Anamnesis: the above complaints have been bothering for more than three years. The last deterioration of health has been since May 2019, wherein, after psychoemotional tension and the assumption of errors in nutrition, the patient began to notice increased pain in the upper abdomen, increased episodes of heartbum, belching sour and bitter, nausea, rumbling in the abdomen, a feeling of distension and fullness, impaired stool, bloating in the abdomen, increased discharge of gases through the intestines. Due to the deterioration of health in June 2019, the patient consulted a gastroenterologist.

[0198] Objectively: the patient’s condition is satisfactory. The nutrition is normal. The skin is clean and has normal color. The mucous membranes are pink. The tongue is overlaid with a white coating. Breathing is vesicular, heart tones are clear, rhythmic. Blood pressure is 110 / 70 mmHg, pulse 68 is beats / min. On palpation, the abdomen is soft and painful in the epigastric and pyloroduodenal regions, the liver and spleen are not enlarged. The stool is mushy, without impurities of mucus and blood (according to the patient’s words).

[0199] The patient was examined in a medical center. According to the FGDS results of 03.06.2019, revealed are: cardia insufficiency, erythematous gastropathy, and duodeno-gastric reflux. A comprehensive diagnosis aimed at detecting Helicobacter pylori infection was carried out. The following methods were used to diagnose Helicobacter pylori infection: biochemical (assessment of urease activity of biopsies taken during FGDS), molecular genetic (PCR of biopsies), bacteriological, and immunochromatographic method (determination of Helicobacter pylori antigen in fecal sample was carried out using the test system H&R H. pylori Vegal Farmaceutica S.L., Spain).

[0200] Helicobacter pylori infection was confirmed by all used methods. Clinical and biochemical blood tests of 05.06.19 were unremarkable. Based on complaints, anamnesis of the disease, objective data and examination results, the following diagnosis was established: chronic HP-associated gastritis, exacerbation. Irritable bowel syndrome in a mixed form.

[0201] Prescribed treatment is: E. faecium-based autoprobiotics, 50 ml twice a day after meals for 1 month in monotherapy, diet, recommendations for lifestyle modification.

[0202] Consultation 2. AFTER using the autoprobiotic.

[0203] After using the autoprobiotic, the patient noted an improvement in health: disappearance of abdominal pain, nausea, feeling of bursting and fullness, bloating in the abdomen, normalization of stool. On palpation, the abdomen is soft and painless in all parts, the liver and spleen are not enlarged. The stool is formed without pathological impurities (according to the patient’s words).

[0204] Control study aimed at identifying Helicobacter pylori was carried out. To control the effectiveness of eradication therapy, the same set of methods was used as in the initial diagnosis of infection. The result of the control study is negative.

[0205] EXAMPLE 12. AUTOPROBIOTIC SUPPORT IN COMPLEX THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (DM2).

[0206] Improving the treatment effectiveness of patients with DM2 by correcting dysbiotic and metabolic disorders using autoprobiotic therapy.

[0207] MA TERIALS AND METHODS

[0208] Human subjects

[0209] 20 patients (15 women and 5 men) of 52±4.7 years old having type 2 diabetes. Autoprobiotic therapy was carried out with a course of 50 ml twice a day for 20 days and then again with the same course in 2 months after the end of the first course. In order to study the dynamics of changes in the intestinal microbiota, the real-time PCR method of a fecal sample DNA was carried out at the stage of inclusion of patients in the study and two weeks after the end of autoprobiotic therapy. In order to assess the effect of the therapy on metabolic processes in the body, the patients’ blood was taken for biochemical analysis before the treatment and 14 days after the end of the treatment course. Psychological status of patients and their quality of life were evaluated using the Beck, Spielberger-Khanin, and SF-36 questionnaires. Comparative statistical analysis was carried out using variance analysis with a posteriori HSD test for unequal N in Software Statistica 8.0. The %2 test with Yates correction was used to compare proportions. Spearman correlations were used to establish statistical relationships between the studied parameters. Differences at p<0.05 were considered significant in all statistical analyses.

[0210] RESULTS

[0211] The results of the intestinal microbiota examination of patients with DM2 have showed that with administration of autoprobiotics, there is a decrease in the total microbial number of the E. coli and B. fragilis population against the background of an increase in more useful B. thetaiotaomicron. Severity of gastroenterological complaints against the background of autoprobiotic therapy in patients significantly decreased - frequency of stools increased from 1.2 to 1.7 times a day, severity of flatulence decreased from 2.6 points to 1.5 points. The effect persisted 3 months after the end of the therapy. The dynamics of laboratory biochemical parameters of patients revealed a significant decrease in the level of CRP in patients of the main group (p<0.05), and positive, but unreliable change in most laboratory parameters. A significant decrease in the titer of opportunistic bacteria in the intestinal microbiota may indicate a beneficial effect of autoprobiotic therapy on the course of diabetes mellitus by correcting dysbiotic disorders, reducing severity of systemic inflammation and reducing the level of insulin resistance.

[0212] EXAMPLE 13. AUTOPROBIOTIC SUPPORT IN COMPLEX THERAPY OF PATIENTS WITH CHOLELITHIASIS.

[0213] Assessment of prospects for improving the effectiveness of surgical treatment of patients with cholelithiasis by correcting dysbiotic disorders using autoprobiotic therapy.

[0214] MA TERIALS AND METHODS

[0215] Human subjects

[0216] 28 patients with cholelithiasis, who underwent elective laparoscopic cholecystectomy.

[0217] The study involved 13 patients (10 women and 3 men) of 57.4±3.2 years old with cholelithiasis as an intervention group. In order to evaluate the clinical efficacy of autoprobiotic therapy, 15 patients with cholelithiasis were selected, who were also scheduled for laparoscopic cholecystectomy, as a comparison group (control group). Psychometric examination before and after the course of autoprobiotic therapy was performed using the Spielberger-Hanin and SF-36 questionnaires. The qualitative and quantitative composition of the gallbladder microbiota was evaluated by the real-time PCR using “Colonoflor-16” reagent kit (AlfaLab LLC, Russia). The intestinal microbiota composition was additionally examined in several patients by metagenomic sequencing on the MiSeq Illumina sequencer according to the protocols used by HMP

[0218] RESULTS

[0219] Comparative analysis of the intestinal microbiome structure in patients of the intervention group against the background of autoprobiotic therapy by metagenomics methods has shown the absence of significant changes in the intestinal microbiome structure in patients with cholelithiasis. Against the background of use of an autoprobiotic product, the severity of pain syndrome and flatulence decreased in the patients, the quality of life improved on scales that assess the physical component of health, and personal anxiety decreased. After the end of the course of autoprobiotic therapy, the intervention group did not differ from the control group in terms of laboratory data and the results of a psychometric examination. However, intensity of a number of gastroenterological complaints was less marked in the autoprobiotic therapy group. The results of biochemical blood tests before and after the course of autoprobiotic therapy have shown a significant decrease in cholesterol and LDL levels, which indicates the effect of the autoprobiotic on metabolic processes in the body due to regulation of hormonal activity of the gastrointestinal tract, the flow of nutrients, bacterial metabolites and bile acids.

[0220] EXAMPLE 14. AUTOPROBIOTIC SUPPORT IN COMPLEX THERAPY OF DENTAL PATIENTS.

[0221] MA TERIALS AND METHODS

[0222] Human subjects

[0223] 37 patients (19 women and 18 men) of 29-64 years old with chronic generalized periodontitis of mild severity without severe concomitant pathology.

[0224] The main group included patients having complex treatment comprising professional oral hygiene, correction of individual hygiene and topical use of an autoprobiotic based on S. salivarius. The control group included patients having treatment of chronic generalized periodontitis of mild severity comprising professional oral hygiene and correction of individual hygiene. Dental parameters were evaluated using hygiene indices and periodontal indices Green- Vermillion (OHI-S), Silness-Loe, CPITN, BOP. Microbiological examination of the contents of periodontal pockets was carried out before and after complex treatment of chronic generalized periodontitis using PCR screening and mass spectrometry (MALDI TOF Microflex LT, Brucker Daltonics, Germany).

[0225] RESULTS

[0226] Prior to the start of treatment, it was found that all patients complained of bleeding during brushing their teeth, swelling and inflammation of the gums. Examination of the oral cavity in all patients before treatment revealed exudation from periodontal pockets (100%), hyperemia of the marginal, attached gum (100%). Four weeks after the complex treatment with the use of an auto- or probiotic, the patients no longer complained of bleeding, swelling and inflammation of the gums, itching, tooth mobility, and presence of an unpleasant odor from the oral cavity. After the use of an autoprobiotic with preliminary professional oral hygiene, there was a decrease of more than 90% in the value of the OHI-S index (p<0.05); the value of the Silness-Loe index decreased by 93% as compared to the value before treatment (p<0.05), and the value of the VOR index decreased by 95% (p<0.05). Based on the CPITN index, it can be revealed that result of the treatment of patients of the main groups is the absence of need for further treatment (index value <1). Monitoring of detection of an autoprobiotic in the periodontal pockets of patients in one month after the end of the treatment using PCR diagnostics was used as control of the effectiveness of using an autoprobiotic in the complex therapy of periodontitis. Prior to the complex treatment of chronic generalized periodontitis of mild severity, anaerobic microorganisms P. gingivalis dominated in periodontal pockets (73% of cases) in all patients. T.forsythia and T.denticola were identified in 43.2% and 29.7% of cases, respectively. P. intermedia was identified in 27% of cases. During and after the treatment, predominance of S. salivarius in the periodontal pockets of patients was observed in 92% of cases, which suggests contribution of the autoprobiotic in regenerative processes in periodontal tissues.

[0227] EXAMPLE 15. AUTOPROBIOTIC SUPPORT IN COMPLEX THERAPY OF CHILDREN WITH BACTERIAL INFECTION. MA TERIALS AND METHODS

[0228] Human subjects

[0229] 23 children of 1-3 years old after acute intestinal infection with laboratory-confirmed bacterial intestinal monoinfection and long-term discharge of pathogenic microorganisms, who received autoprobiotics as part of complex therapy.

[0230] Clinical observation of patients in the hospital was carried out daily. The severity of acute intestinal infection was evaluated by the severity and duration of the persistence of diarrhea, vomiting, fever and changes in the general condition of the child using the Clark scale. All patients in the hospital received standard complex therapy, including diet therapy, use of sorbents and enzyme preparations (if medically required). Verification of the causative agent of acute intestinal infection was carried out using molecular genetic examination of fecal samples by PCR using "AmpliSens® OKI screen-FL” reagent kit. Nosological structure of intestinal infections in patients included in the study: campylobacteriosis 79.1%, escherichiosis 9.3%, salmonellosis 11.6%. Correction of dysbiotic disorders in children after acute intestinal infection was carried out using the Enterococcus faecium-based autoprobiotic. The real-time PCR method (“Colonoflor-16”, AlfaLab LLC, Russia) was used to diagnose the state of microbiota. The children received autoprobiotics grown from individual strains of 25 ml twice a day for 10 days. Criteria for recovery were clinical indicators - the absence of dyspeptic complaints, normalization of stool, temperature, appetite, body weight; as well as laboratory signs - normalization of hemogram parameters, biochemical blood test, general urinalysis, coprogram.

[0231] RESULTS

[0232] The absence of pathogenic microorganisms with the background use of Enterococcus faecium- based autoprobiotics during the recovery period after acute intestinal infection has been shown. A good tolerance of autoprobiotics in children and faster recovery of the microbiota composition in terms of the main indicators (Lactobacilli, Bifidobacteria, Enterococcus, Akkermansia) (p<0.05) has been revealed. Against the background of complex therapy, there was a decrease in abdominal pain, rapid saturation, and most patients had an improvement in terms of coprogram. Elimination of the pathogen was achieved in all patients receiving the autoprobiotic. References:

[0233] [1] Bondarenko VM, Chuprinina RP, Matsulevich TV, Aladysheva GI. Probiotics and mechanisms of their therapeutic action. Experimental and clinical gastroenterology 2004; 3: 83- 87. (in Russian)

[0234] [2] Ruchkina IN, Parfenov Al, Osipov AG. Features of complex therapy of post-infectious irritable bowel syndrome. Gastroenterology of St. Petersburg 2007; 1-2: 94. (in Russian)

[0235] [3] Suvorov AN. The use of probiotics for the prevention and treatment of various diseases. St. Petersburg 2004; 32 p. (in Russian)

[0236] [4] Collins MD, Gibson GR. Probiotics, prebiotics and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999; 69: 1052-1057.

[0237] [5] Petrov LN, Verbitskaya NB et al. Bacterial probiotics: biotechnology, clinic, selection algorithms. St. Petersburg 2008; 136 p. (in Russian)

[0238] [6] Kelly D, Conway S, Aminov R. Commensal gut bacteria: mechanism of immune modulation. Trends Immunol 2005; 26: 326-333.

[0239] [7] Boirivant M, Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol 2007; 23(6): 679-92.

[0240] [8] Shenderov BA. Medical microbial ecology and functional nutrition, V. III. Moscow 2001; 287 p. (in Russian)

[0241] [9] Korshunov VM, Sinitsina NA, Pinegin BV, Ginodman GA. A method for treatment of intestinal dysbacteriosis. SU1286212 (1987). (in Russian)

[0242]

[0010] Shenderov BA, Manvel ova MA. A method of preparing an autoprobiotic containing living bifidobacterium and lactobacilli. RU2139070 (1999). (in Russian)

[0243]

[0011] Suvorov AN, Simanenkov VI, Sundukova ZR, Ermolenko El, Tsapieva AN, Donets VN, Solovyova OI. A method for producing an autoprobiotic based on Enterococcus faecium, a representative of indigenous gut microflora. RU2460778 (2012). (in Russian)

[0244]

[0012] Simanenkov VI, Suvorov AN, Solovyova OI, Tsapieva AN, Shumikhina IA. A method for prevention of post-infectious irritable bowel syndrome. RU2553372 (2015). (in Russian)

[0245]

[0013] Ermolenko El, Milyukhina IV, Tsapieva AN, Alekhina GG, Istomina AS, Gracheva EV, Kopyleva MP, Suvorov AN. A method for reducing the severity of non-motor symptoms in patients suffering from Parkinson's disease. RU2734718 (2020). (in Russian)

[0014] Simanenkov VI, Suvorov AN, Solovyova 01, Ermolenko El, Tsapieva AN, Sundukova ZR. A method for obtaining a personalized autoprobiotic product and a method for treating irritable bowel syndrome using this product. RU2546253 (2015). (in Russian)

[0246]

[0015] Kuznetsov OY, Kuznetsova LA, Kuznetsov AO, Borisova EM, Safonova MA. A method for obtaining an autoprobiotic containing live bifidobacterium and lactobacilli. RU2505304 (2014). (in Russian)

[0247]

[0016] Denisov DE, Kuznetsova TN. A method for obtaining an autoprobiotic containing live bifidobacterium and lactobacilli. RU2580002 (2016). (in Russian)

[0248]

[0017] Vlasov VV, Shevela Al, Morozov VV, Shrainer EV, Kulikov VG. A method for treating irritable bowel syndrome. RU2661624 (2018). (in Russian)

[0249]

[0018] Ickert OP, Petrov VA, Dorofeeva JB, Nevskaya KV. A method for isolation and preservation of total human intestinal microbiota for transplantation. RU2727444 (2020). (in Russian)

[0250]

[0019] Poluektova EU, Danilenko VN. A method for species identification of lactobacilli L. casei / paracasei. L. fermenlum. L. plantarum and L. rhamnosus. RU2508406 (2014). (in Russian)

[0251]

[0020] Popenko AS, Tyakht AV, Alekseev DG, Klimenko NS, Filipenko ML, Shadrina AS. A detection system for the most significant prokaryotic representatives of human intestinal microbiota based on PCR panel. RU2680268 (2019). (in Russian)

[0252]

[0021] Zachary A, Richman J, Almonacid D, Valdivia C, Ortiz R, Pedroso I, Dumas V, Tapia P, Morales E. Method and system for characterizing allergy-related conditions associated with microorganisms. US10381112 (2019).

[0253]

[0022] Zachary A, Richman J, Almonacid D, Pedroso I, Valdivia C, Ortiz R, Tapia P. Method and system for characterizing microorganism-associated sleep-related conditions. US10395777 (2019).

[0254]

[0023] Gordon JI, Subramanian S, Hsiao A. Methods to establish and restore normal gut microbiota function of subject in need thereof. US10920283 (2021).

[0255]

[0024] George JM, Bralley JA. Process and method for monitoring gastrointestinal microbiota. WO2009123736 (2009).

[0025] Jain S. Universal method for extracting nucleic acid molecules from a diverse population of microbes. W02020087046 (2020).

[0256]

[0026] Farmer S, Alibek K, Tskhay A. Personalized system for restoring the gastrointestinal tract microbiome. US2021381024 (2021).

[0257]

[0027] Alekhina GG, Suvorov AN. A probiotic composition with high antagonistic activity against opportunistic and pathogenic microflora for therapeutic and preventive medicines and method for producing thereof. RU2227039 (2004). (in Russian)

[0258]

[0028] http: / / www.ncbi.nlm.nih.gov / BLAST

Claims

CLAIMS1. A method of producing an autoprobiotic formulation based on indigenous microbiota of a subject, the method comprising:(a) taking a fecal microbiota sample from the subject, wherein said sample comprises indigenous bacteria of said subject;(b) growing a fecal microbiota sample from stage (a) on selective culture medium;(c) identifying the strains of indigenous bacteria obtained at stage (b);(d) obtaining pure cultures of identified strains from stage (c);(e) genetically analyzing the strains of indigenous bacteria obtained at stage (d) for assessing their safety;(f) excluding the presence of pathogenic determinants;(g) selecting genetically safe strains of indigenous bacteria obtained at stage (d);(h) preparing an autoprobiotic formulation based on genetically safe strains of indigenous bacteria obtained at stages (e)-(g); wherein the autoprobiotic formulation is personalized, and wherein specific strains of indigenous bacteria to be included into the autoprobiotic formulation are selected by a medical specialist after receiving assessment data for a current health condition of the subject.

2. The method of claim 1, further comprising the stage of storage of genetically safe strains of indigenous bacteria obtained at stages (e)-(g) in a cryobank after stage (g).

3. The method of claim 2, wherein the storage temperature is from -20 °C to -195 °C, preferably -80°C.

4. The method of claims 2-3, wherein the storage period is from one day to one year.

5. The method of claims 2-3, wherein the storage period is more than one year.

6. The method of claim 5, wherein the storage period is unlimited.

7. The method of any one of claims 2-6, wherein genetically safe strains of indigenous bacteria are stored in the cryobank as pure cultures.

8. The method of claim 1, wherein said assessment data for a current health condition of the subject comprises test results.

9. The method of claim 8, wherein said test results include one or more obtained from bacteriological culturing of the subject’s microbiota sample, assessment of current microbiotacomposition by quantitative PCR, metagenomic microbiota analysis or combined gas chromatography mass-spectrometry analysis.

10. The method of claims 1-9, wherein the autoprobiotic formulation is monocomponent or polycomponent.

11. The method of claim 10, wherein the autoprobiotic formulation comprises one or more of species Lactobacillus spp., Lactococcus spp., Enterococcus spp., Streptococcus spp., Bifidobacterium spp., E.coli, Akkermansia spp., Hafnia alvei.

12. The method of claims 1-11, wherein stage (c) is accomplished using microbiology and molecular genetic methods.

13. The method of claims 1-12, wherein stages (e)-(g) are accomplished using PCR with primers homologous to known pathogenic determinants and sequencing of specific parts of indigenous bacteria genome.

14. The method of claim 13, wherein said pathogenic determinants are genes encoding one or more factors selected from hemolysins, adhesins, proteases, cytolysins, toxins.

15. An autoprobiotic formulation based on indigenous microbiota of a subject comprising genetically safe strains of indigenous bacteria, wherein the autoprobiotic formulation is produced by the method according to any one of claims 1-14.

16. The autoprobiotic formulation of claim 15, further comprising an excipient, diluent or carrier.

17. The autoprobiotic formulation of claims 15-16, formulated for oral, topical or intravaginal administration.

18. The autoprobiotic formulation of claims 15-16, formulated in the form of a capsule, tablet, solution, cream, powder or suppository.

19. The autoprobiotic formulation of claims 15-18 for use in the method of treating a disease or disorder in a subject in need thereof.

20. The autoprobiotic formulation for use of claim 19, wherein the method further comprises receiving assessment data for a current health condition of the subject by a medical specialist before administering the autoprobiotic formulation.

21. The autoprobiotic formulation for use of claims 19-20, wherein specific strains of indigenous bacteria to be included into the autoprobiotic formulation for treating a disease or disorder in said subject are selected by a medical specialist after receiving assessment data for a current health condition of the subject.

22. The autoprobiotic formulation for use of claims 19-21, wherein said assessment data for a current health condition of the subject comprises test results.

23. The autoprobiotic formulation for use of claim 22, wherein said test results include one or more obtained from bacteriological culturing of the subject’s microbiota sample, assessment of current microbiota composition by quantitative PCR, metagenomic microbiota analysis or combined gas chromatography mass-spectrometry analysis.

24. The autoprobiotic formulation for use of claims 19-23, wherein the autoprobiotic formulation is administered orally.

25. The autoprobiotic formulation for use of claims 19-23, wherein the autoprobiotic formulation is administered on the skin.

26. The autoprobiotic formulation for use of claims 19-23, wherein the autoprobiotic formulation is administered into vaginal cavity.

27. The autoprobiotic formulation for use of claims 19-26, wherein the autoprobiotic formulation is administered to the subject once a day, twice a day or three times a day.

28. The autoprobiotic formulation for use of claims 19-27, wherein the autoprobiotic formulation is administered to the subject for one week, for two weeks, for three weeks or for a month.

29. The autoprobiotic formulation for use of claims 19-28, wherein a disease or disorder is selected from the group comprising dysbiosis, inflammatory bowel disease, irritable bowel syndrome, diabetes mellitus, bacterial infection, cancer, neurodegenerative disorder, gastritis, cholelithiasis, dental diseases and other pathological conditions accompanied by a disturbance of intestinal microbiota.

Citation Information

Patent Citations

  • Method of preparing autoprobiotic containing living bifid bacteria and lactobacilli

    RU2139070C1

  • Probiotic composition with high antagonistic activity with respect to opportunistic and pathogenic microflora for curative-prophylactic agents and method for its preparing

    RU2227039C2

  • Method for producing autoprobiotic of enterocuccus faecium being representative of indigenic host intestinal microflora

    RU2460778C1

  • Method for preparing autoprobiotic containing living bifidus bacteria and lactic acid bacilli

    RU2505304C2

  • METHOD OF SPECIES IDENTIFICATION OF L.casei / paracasei, L.fermentum, L.plantarum AND L.rhamnosus

    RU2508406C2